In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Acura Pharmaceuticals Inc (NASDAQ:ACUR) reported that Schutte John has picked up 10,695,186 of common stock as of 2017-08-03.
The acquisition brings the aggregate amount owned by Schutte John to a total of 10,695,186 representing a 47.5% in the company.
For those not familiar with the company, Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested.
A glance at Acura Pharmaceuticals Inc (NASDAQ:ACUR)’s key stats reveals a current market capitalization of 6.18M based on 11.88M shares outstanding and a price at last close of $0.520 per share
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2014-05-19, Rivet picked up 2,000 at a purchase price of $1.23 per share.This brings their total holding to 2,000 as of the date of the filing.
On the sell side, the most recent transaction saw Claudius unload 3,900 shares at a sale price of $1.05. This brings their total holding to 10,978,674.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Acura Pharmaceuticals Inc (NASDAQ:ACUR) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.